logo

For the Inventor, By the Inventor

Arlington, MA, United States of America

David John O'Neill

This inventor holds 16 USPTO granted patents and 6 published patent applications and 2 EPO patents, primarily in mTOR Inhibitors. Top assignees: Navitor Pharmaceuticals, Inc., Janssen Pharmaceutica Nv, Janssen Pharmaceutica. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David John O'Neill. Retrieved from https://idiyas.com/inventor/david-john-o-neill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 62.5

 

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 64(Granted Patents)


Location History:

  • Flemington, NJ (US) (2006 - 2010)
  • Arlington, MA (US) (2018 - 2024)

Company Filing History:

goldMedal9 out of 18 
 
Navitor Pharmaceuticals, Inc.
 patents
silverMedal6 out of 2,103 
 
Janssen Pharmaceutica Nv
 patents
bronzeMedal1 out of 32 
 
Janssen Pharmaceutica
 patents

Years Active: 2006-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
mTORC Inhibitors
Rapamycin Analogs
Sestrin-GATOR2
Phenyl Amino Piperidine
Substituted Pyrroline
Kinase Inhibitors
Modulators
Drug Development
Biochemistry
Pharmaceuticals
16 patents (USPTO):Explore Patents
1. 12378263 - Modulators of sestrin-GATOR2 interaction and uses thereof (2025-08-05),
2. 11944605 - Rapamycin analogs and uses thereof (2024-04-02),
3. 11819476 - Rapamycin analogs and uses thereof (2023-11-21),
4. 11325924 - Modulators of Sestrin-GATOR2 interaction and uses thereof (2022-05-10),
5. 10980784 - Rapamycin analogs and uses thereof (2021-04-20),
6. 10844013 - Phenyl amino piperidine mTORC inhibitors and uses thereof (2020-11-24),
7. 10752644 - Modulators of Sestrin-GATOR2 interaction and uses thereof (2020-08-25),
8. 10683308 - Rapamycin analogs and uses thereof (2020-06-16),
9. 10414782 - Modulators of sestrin-GATOR2 interaction and uses thereof (2019-09-17),
10. 10414727 - Phenyl amino piperidine mTORC inhibitors and uses thereof (2019-09-17),
11. 10100066 - Modulators of sestrin-GATOR2 interaction and uses thereof (2018-10-16),
12. 7786135 - Substituted pyrroline kinase inhibitors (2010-08-31),
13. 7781450 - Substituted pyrroline kinase inhibitors (2010-08-24),
14. 7705015 - Substituted pyrroline kinase inhibitors (2010-04-27),
15. 7524858 - Substituted pyrroline kinase inhibitors (2009-04-28),

Title: The Innovative Mind of David John O'Neill

Introduction:

David John O'Neill, a visionary inventor based in Arlington, MA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents:

David John O'Neill holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovation.

Career Highlights:

Throughout his illustrious career, David John O'Neill has been recognized for his pioneering work in developing cutting-edge solutions that have revolutionized industries. His commitment to pushing the boundaries of innovation has led to the creation of impactful technologies that have improved the lives of many.

Collaborations:

David John O'Neill has collaborated with leading research institutions, universities, and tech companies to further his inventions and bring them to market. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion:

In conclusion, David John O'Neill stands as a beacon of innovation in the technological landscape, continuously striving to create solutions that address complex challenges and drive progress in society. His passion for innovation and dedication to his craft make him a true pioneer in the world of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…